Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease

BIOCYCLE group

Research output: Contribution to journalShort surveypeer-review

10 Scopus citations

Abstract

In Crohn's disease, combination therapy with anti–tumor necrosis factor (anti-TNF) agents and azathioprine/mercaptopurine has been shown to be superior to monotherapy with one of these treatments alone.1 This combination has its best success rate when used early in the course of treatment.2 However, because of the significant cost of these drugs and concerns over long-term side effects,3,4 many patients and providers often ask about stopping one or both of these medications.

Original languageEnglish
Pages (from-to)403-405
Number of pages3
JournalClinical Gastroenterology and Hepatology
Volume19
Issue number2
DOIs
StatePublished - Feb 2021

Fingerprint

Dive into the research topics of 'Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohn's Disease'. Together they form a unique fingerprint.

Cite this